MA47408B1 - Traitement du cancer - Google Patents

Traitement du cancer

Info

Publication number
MA47408B1
MA47408B1 MA47408A MA47408A MA47408B1 MA 47408 B1 MA47408 B1 MA 47408B1 MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A MA 47408 B1 MA47408 B1 MA 47408B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
erdafitinib
relates
present
treating cancer
Prior art date
Application number
MA47408A
Other languages
English (en)
Other versions
MA47408A (fr
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/fr
Publication of MA47408B1 publication Critical patent/MA47408B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de traitement du cancer par l'erdafitinib
MA47408A 2017-12-20 2018-02-02 Traitement du cancer MA47408B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (fr) 2017-02-06 2018-02-02 Traitement du cancer

Publications (2)

Publication Number Publication Date
MA47408A MA47408A (fr) 2019-12-11
MA47408B1 true MA47408B1 (fr) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (fr) 2017-12-20 2018-02-02 Traitement du cancer

Country Status (5)

Country Link
EA (1) EA201991818A1 (fr)
MA (1) MA47408B1 (fr)
PT (1) PT3576740T (fr)
TW (1) TWI798199B (fr)
WO (1) WO2018141921A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020058432A1 (fr) * 2018-09-21 2020-03-26 Janssen Pharmaceutica Nv Traitement du cholangiocarcinome
EP3898626A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
EP3923942A1 (fr) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Traitement contre le cancer
US20220202703A1 (en) * 2019-03-15 2022-06-30 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
PH12021552342A1 (en) * 2019-03-29 2022-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
AU2020282816A1 (en) * 2019-05-31 2022-01-06 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CA3176713A1 (fr) 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Utilisation d'inhibiteurs de fgfr pour le traitement de sujets presentant un retard de croissance idiopathique
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
TWI900527B (zh) * 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
WO2022061075A1 (fr) * 2020-09-17 2022-03-24 Ayala Pharmaceuticals Inc. Compositions comprenant des composés de bisfluoroalkyl-1,4-benzodiazépinone pour traiter un carcinome adénoïde kystique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物

Also Published As

Publication number Publication date
WO2018141921A1 (fr) 2018-08-09
PT3576740T (pt) 2023-08-18
TWI798199B (zh) 2023-04-11
EA201991818A1 (ru) 2020-02-05
MA47408A (fr) 2019-12-11
TW201839399A (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
MA47408B1 (fr) Traitement du cancer
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
EP3478286A4 (fr) Méthodes de traitement du cancer de l'ovaire
EP3813806A4 (fr) Méthodes de traitement d'un dysfonctionnement mitochondrial
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EP2992908A4 (fr) Procédé de traitement de la surface d'un implant
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
EP3820461A4 (fr) Méthode de traitement du cancer
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
EP3580185A4 (fr) Procédé de traitement de boue
EP3937964A4 (fr) Traitement de cancers induits par des oncogènes
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
EP3775171A4 (fr) Procédés de traitement d'un cancer résiduel minimal
EP3684342A4 (fr) Procédé de traitement
EA201792610A1 (ru) Способ лечения неврологического заболевания
EP3952858A4 (fr) Procédé de traitement de tumeurs
EP3769897A4 (fr) Machine de traitement par laser et procédé de traitement par laser
EP3638630C0 (fr) Procédé de traitement de boues
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3947296A4 (fr) Procédé de traitement des eaux usées
EP3407858A4 (fr) Méthode de traitement de l'aspect dégarni des cheveux
EP3672689A4 (fr) Procédé de traitement d'une tumeur neuroendocrine
EP3713576A4 (fr) Méthodes de traitement du cancer
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap
EP3967371A4 (fr) Procédé de traitement capillaire